gefurulimab gefurulimab PHASE3
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaRare Disease
Peak Sales Est$1200M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: C5 inhibitor
Expert: Humanized monoclonal antibody that binds complement C5, preventing cleavage to C5a and C5b and inhibiting terminal complement-mediated hemolysis and inflammation.
Everyday: Blocks a protein in the immune system that mistakenly attacks the body's own red blood cells.
Targets: ["C5"]
Programs (2)
IndicationStageKey StudyRegional Status
IgANPHASE3RAINIER[]
gMGPHASE3NIPPON[]
Notes
Subcutaneous C5 inhibitor for gMG.
Data from Supabase · Updated 2026-03-24